Article | August 24, 2022

Unlocking The Potential Of Plasma Biomarkers In CNS Trials For Alzheimer's Disease

By Olja Tanjga, MD, Senior Medical Director, IQVIA Biotech and Alistair Watt, Global Senior Director, Translational Science Laboratory, Q2 Solutions

The End To End Importance Of Selecting The Right Biomarker In Cancer Studies

In recent years, scientists have been exploring the use of plasma biomarkers as a non-invasive and cost-effective diagnostic tool for Alzheimer's disease. This option may predict both pathological and clinical changes in those with underlying Alzheimer's, providing a less invasive and less costly way to identify patients who could be candidates for clinical trials or therapies.5

While still in early stages for identifying signs and progression of AD, plasma biomarkers show great promise. P-tau appears to have a high degree of accuracy in plasma for Alzheimer's disease and plasma Aβ measures also have potential. Less invasive and more affordable blood-based biomarker testing along with genetic, clinical and demographic information will likely play an important screening role in selecting individuals for more expensive and invasive biomarker testing.6

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader